摘要
目的从全社会的角度评价雷珠单抗和康柏西普治疗湿性老年黄斑病变的经济性。方法通过文献研究方法获得两种干预措施治疗湿性老年黄斑病变的临床及产出数据,并结合国内治疗成本数据通过构建Markov模型对20年内两种用药方案下的疾病转归、效用及成本进行计算,通过成本-效用分析对湿性老年黄斑病变的两种用药方案进行药物经济学评价。结果雷珠单抗组的治疗总成本为1691 608.9元,可使患者获得10.46个QALY;康柏西普组的治疗总成本为1201 730.9元,可使患者获得7.85个QALY,雷珠单抗相比康柏西普,每增加一个QALY需要多消耗187 692.72元,大于我国3倍人均GDP,所以康柏西普更经济,单因素和概率敏感性分析证明了结果的稳健性。结论对于湿性老年黄斑病变的药物治疗,康柏西普更具有经济性。
Objective To evaluate the economics of the treatment of wettable senile macular lesions by using Tripteryzumab and Compactopril from the whole society.Methods The clinical, output data and cost data of two kinds of interventions in the treatment of wet senile macular disease were obtained by literature study. The Markov model was constructed to calculate the outcome, utility and cost of the disease under the two drug use schemes in the next 20 years. The pharmacoeconomic evaluation of two drug regimens for wettable senile macular disease was carried out by cost-utility analysis.Results The total cost of treatment was 1691,608.9 yuan in the Leizhu McAb group. It can get 10.46 QALYs; The total cost of treatment in the Compactopril group was 1201,730.9 yuan, and the patient received 7.85 QALYs, compared with Combortopril. Each additional QALY needs to consume more than 187,692.72 yuan, which is more than three times the average per capita in our country, so Compathep is more economical. Univariate and probabilistic sensitivity analysis demonstrated the robustness of the results.Conclusion Compactopril is more economical for the treatment of wet senile macular disease.
作者
马爱霞
张籍元
MAAi-xia;ZHANG Ji-yuan
出处
《中国药物经济学》
2018年第9期27-31,共5页
China Journal of Pharmaceutical Economics
